1
|
Hartmann K, Möstl K, Lloret A, Thiry E, Addie DD, Belák S, Boucraut-Baralon C, Egberink H, Frymus T, Hofmann-Lehmann R, Lutz H, Marsilio F, Pennisi MG, Tasker S, Truyen U, Hosie MJ. Vaccination of Immunocompromised Cats. Viruses 2022; 14:v14050923. [PMID: 35632665 PMCID: PMC9147348 DOI: 10.3390/v14050923] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2022] [Revised: 04/25/2022] [Accepted: 04/26/2022] [Indexed: 02/01/2023] Open
Abstract
Immunocompromise is a common condition in cats, especially due to widespread infections with immunosuppressive viruses, such as feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV), but also due to chronic non-infectious diseases, such as tumours, diabetes mellitus, and chronic kidney disease, as well as treatment with immunosuppressive drugs, such as glucocorticoids, cyclosporins, or tumour chemotherapy. In this review, the European Advisory Board on Cat Diseases (ABCD), a scientifically independent board of experts in feline medicine from eleven European countries, discusses the current knowledge and rationale for vaccination of immunocompromised cats. So far, there are few data available on vaccination of immunocompromised cats, and sometimes studies produce controversial results. Thus, this guideline summarizes the available scientific studies and fills in the gaps with expert opinion, where scientific studies are missing. Ultimately, this review aims to help veterinarians with their decision-making in how best to vaccinate immunocompromised cats.
Collapse
Affiliation(s)
- Katrin Hartmann
- Clinic of Small Animal Medicine, Centre for Clinical Veterinary Medicine, LMU Munich, 80539 Munich, Germany
- Correspondence:
| | - Karin Möstl
- Institute of Virology, Department for Pathobiology, University of Veterinary Medicine, 1210 Vienna, Austria;
| | - Albert Lloret
- Fundació Hospital Clínic Veterinari, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain;
| | - Etienne Thiry
- Veterinary Virology and Animal Viral Diseases, Department of Infectious and Parasitic Diseases, FARAH Research Centre, Faculty of Veterinary Medicine, Liège University, 4000 Liège, Belgium;
| | - Diane D. Addie
- Veterinary Diagnostic Services, School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G61 1QH, UK;
| | - Sándor Belák
- Department of Biomedical Sciences and Veterinary Public Health (BVF), Swedish University of Agricultural Sciences (SLU), 750 07 Uppsala, Sweden;
| | | | - Herman Egberink
- Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, University of Utrecht, 3584 CL Utrecht, The Netherlands;
| | - Tadeusz Frymus
- Department of Small Animal Diseases with Clinic, Institute of Veterinary Medicine, Warsaw University of Life Sciences-SGGW, 02-787 Warsaw, Poland;
| | - Regina Hofmann-Lehmann
- Clinical Laboratory, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland; (R.H.-L.); (H.L.)
| | - Hans Lutz
- Clinical Laboratory, Department of Clinical Diagnostics and Services, Vetsuisse Faculty, University of Zurich, 8057 Zurich, Switzerland; (R.H.-L.); (H.L.)
| | - Fulvio Marsilio
- Faculty of Veterinary Medicine, Università Degli Studi di Teramo, 64100 Teramo, Italy;
| | - Maria Grazia Pennisi
- Dipartimento di Scienze Veterinarie, Università di Messina, 98168 Messina, Italy;
| | - Séverine Tasker
- Bristol Veterinary School, University of Bristol, Bristol BS40 5DU, UK;
- Linnaeus Veterinary Ltd., Shirley, Solihull B90 4BN, UK
| | - Uwe Truyen
- Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, 04103 Leipzig, Germany;
| | - Margaret J. Hosie
- MRC—University of Glasgow Centre for Virus Research, Glasgow G61 1QH, UK;
| |
Collapse
|
2
|
Stanossek I, Wehrend A. [Naturopathy and complementary medicine in small animal science - definitions and contents]. TIERAERZTLICHE PRAXIS AUSGABE KLEINTIERE HEIMTIERE 2021; 49:206-210. [PMID: 34157762 DOI: 10.1055/a-1480-5642] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Naturopathic and complementary procedures attain increasing popularity in veterinary medicine. A common understanding of definitions and contents of these fields is crucial for communication between pet owners and veterinarians. This paper reviews the existing definitions and the various contents of naturopathy and complementary veterinary medicine as well as their assigned treatment options. Naturopathy includes phytotherapy, hydro-therapy, thermotherapy, electrotherapy, manual therapy/chiropractic/osteopathy, and dietetic treatment. Homeopathy, homotoxicology, Traditional Chinese Medicine including acu-puncture and Chinese herbal medicine, neural therapy, organotherapy and Bach flower remedies are known as complementary treatments. The level of evidence based on scientific literature and the opportunity for certification procedures differ between treatment modalities. In the area of small animal medicine, the most extensive body of literature is available on the subject of acupuncture, in part comprising high evidence levels.
Collapse
Affiliation(s)
- Ines Stanossek
- Klinik für Geburtshilfe, Gynäkologie und Andrologie der Groß- und Kleintiere mit Tierärztlicher Ambulanz, Justus-Liebig-Universität Gießen
| | | |
Collapse
|
3
|
Bergmann M, Freisl M, Hartmann K, Speck S, Truyen U, Zablotski Y, Mayr M, Wehner A. Antibody Response to Canine Parvovirus Vaccination in Dogs with Hypothyroidism Treated with Levothyroxine. Vaccines (Basel) 2021; 9:vaccines9020180. [PMID: 33672564 PMCID: PMC7924029 DOI: 10.3390/vaccines9020180] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2021] [Revised: 02/10/2021] [Accepted: 02/14/2021] [Indexed: 11/25/2022] Open
Abstract
(1) Background: No information is available on how dogs with hypothyroidism (HypoT) respond to vaccination. This study measured pre- and post-vaccination anti-canine parvovirus (CPV) antibodies in dogs with HypoT treated with levothyroxine and compared the results to those of healthy dogs. (2) Methods: Six dogs with HypoT and healthy age-matched control dogs (n = 23) were vaccinated against CPV with a modified-live vaccine. Hemagglutination inhibition was used to measure antibodies on days 0, 7, and 28. The comparison of the vaccination response of dogs with HypoT and healthy dogs were performed with univariate analysis. (3) Results: Pre-vaccination antibodies (≥10) were detected in 100% of dogs with HypoT (6/6; 95% CI: 55.7–100) and in 100% of healthy dogs (23/23; 95% CI: 83.1–100.0). A ≥4-fold titer increase was observed in none of the dogs with HypoT and in 4.3% of the healthy dogs (1/23; CI95%: <0.01–22.7). Mild vaccine-associated adverse events (VAAEs) were detected in 33.3% of the dogs with HypoT (2/6; 95% CI: 9.3–70.4) and in 43.5% (10/23; 95% CI: 25.6–63.2) of the healthy dogs. (4) Conclusions: There was neither a significant difference in the dogs’ pre-vaccination antibodies (p = 1.000), or vaccination response (p = 0.735), nor in the occurrence of post-vaccination VAAEs (p = 0.798). The vaccination response in dogs with levothyroxine-treated HypoT seems to be similar to that of healthy dogs.
Collapse
Affiliation(s)
- Michèle Bergmann
- Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (M.F.); (K.H.); (Y.Z.); (M.M.); (A.W.)
- Correspondence: ; Tel.: +49-89-2180-2651
| | - Monika Freisl
- Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (M.F.); (K.H.); (Y.Z.); (M.M.); (A.W.)
| | - Katrin Hartmann
- Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (M.F.); (K.H.); (Y.Z.); (M.M.); (A.W.)
| | - Stephanie Speck
- Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany; (S.S.); (U.T.)
| | - Uwe Truyen
- Institute of Animal Hygiene and Veterinary Public Health, University of Leipzig, An den Tierkliniken 1, 04103 Leipzig, Germany; (S.S.); (U.T.)
| | - Yury Zablotski
- Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (M.F.); (K.H.); (Y.Z.); (M.M.); (A.W.)
| | - Matthias Mayr
- Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (M.F.); (K.H.); (Y.Z.); (M.M.); (A.W.)
| | - Astrid Wehner
- Clinic of Small Animal Medicine, LMU Munich, Veterinaerstrasse 13, 80539 Munich, Germany; (M.F.); (K.H.); (Y.Z.); (M.M.); (A.W.)
| |
Collapse
|
4
|
Bergmann M, Freisl M, Hartmann K. [Prevention of canine parvovirosis - Part 1: Humoral and cellular immunity]. TIERAERZTLICHE PRAXIS AUSGABE KLEINTIERE HEIMTIERE 2021; 49:44-50. [PMID: 33588464 DOI: 10.1055/a-1319-4564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Canine parvovirosis remains a common and highly infectious disease. Thus, adequate protection is essential for all dogs at any time. In this, humoral immunity plays an essential role. The presence of antibodies in adult dogs suggests immunity against the disease, and nearly all adult dogs possess antibodies (either due to previous vaccination or infection). Meanwhile, worldwide vaccination guidelines recommend measurement of pre-vaccination antibodies instead of regular triennial re-vaccinations in adult dogs. Studies have demonstrated a long lasting duration of immunity against canine parvovirus. Re-vaccination therefore possesses no beneficial effect when dogs already have pre-vaccination antibodies. Thus, when antibodies are present, unnecessary re-vaccinations that potentially cause vaccine-associated adverse events should be avoided. Hemagglutination inhibition and virus neutralization can be performed in specialized laboratories for quantitative antibody titer measurement. Semiquantitative point-of-care (POC) tests for detection of CPV antibodies are available. Since the presence of CPV antibodies in adult dogs that have been vaccinated or previously infected suggests adequate immunity against disease, these POC tests can be a useful tool in practice. They identify dogs that might potentially be unprotected and require re-vaccination during preventive health care appointments. Concerning the POC tests' quality assessment, a high specificity (low number of false positive test results) is considered the most important feature.
Collapse
Affiliation(s)
- Michèle Bergmann
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| | - Monika Freisl
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| | - Katrin Hartmann
- Medizinische Kleintierklinik, Ludwig-Maximilians-Universität München
| |
Collapse
|
5
|
Dodds WJ. Early Life Vaccination of Companion Animal Pets. Vaccines (Basel) 2021; 9:92. [PMID: 33513703 PMCID: PMC7910975 DOI: 10.3390/vaccines9020092] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2020] [Revised: 01/12/2021] [Accepted: 01/22/2021] [Indexed: 12/03/2022] Open
Abstract
Development of the immune system of mammalian animal species parallels that of humans and involves the innate and adaptive (acquired) immune responses acting together with the thymus gland. Consequently, issues surrounding the adequacy and safety of vaccinations to protect pet animals from their relevant infectious diseases need to be addressed just as they are for humans. Pet animals, especially canines, also have unique needs because of the wide diversity of purebred and mixed breeds that vary greatly in size, type, temperament, and even maturation rates. Furthermore, pets in early life encounter a series of changes that can affect their development and induce stressors including parasite control, new homes and environment, novel foods, and the socialization that is essential at a time when vaccinations need to be given. While recognizing that this overall need is becoming more understood, current vaccination policy guidelines for companion animals are still only adhered to by about 40% of veterinarians worldwide. Clearly, vaccination of pets should no longer be considered as "one size fits all".
Collapse
Affiliation(s)
- W Jean Dodds
- Hemopet, 11561 Salinaz Avenue, Garden Grove, CA 92843, USA
| |
Collapse
|
6
|
Antibody Response to Canine Parvovirus Vaccination in Dogs with Hyperadrenocorticism Treated with Trilostane. Vaccines (Basel) 2020; 8:vaccines8030547. [PMID: 32961758 PMCID: PMC7563131 DOI: 10.3390/vaccines8030547] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2020] [Revised: 09/14/2020] [Accepted: 09/15/2020] [Indexed: 11/18/2022] Open
Abstract
It is unknown how dogs with hyperadrenocorticism (HAC) respond to vaccination. This study measured antibodies against canine parvovirus (CPV) in dogs with HAC treated with trilostane before and after CPV vaccination, and compared the immune response to that from healthy dogs. Eleven dogs with HAC, and healthy age-matched control dogs (n = 31) received a modified-live CPV vaccine. Antibodies were determined on days 0, 7, and 28 by hemagglutination inhibition. Univariate analysis was used to compare the immune response of dogs with HAC and healthy dogs. Pre-vaccination antibodies (≥10) were detected in 100% of dogs with HAC (11/11; 95% CI: 70.0–100) and in 93.5% of healthy dogs (29/31; 95% CI: 78.3–99.2). No ≥4-fold increase in antibody titer was observed in dogs with HAC while in 22.6% of healthy dogs, a ≥4-fold titer increase was observed (7/31; 95% CI: 11.1–40.1). Mild vaccine-associated adverse events (VAAEs) were detected in 54.5% of dogs with HAC (6/11; 95% CI: 28.0–78.8) and in 29.0% of healthy dogs (9/31; 95% CI: 15.9–46.8). There was neither a significant difference in presence of pre-vaccination antibodies (p = 1.000), or response to vaccination (p = 0.161), nor in the occurrence of VAAEs (p = 0.158). Immune function of dogs with HAC treated with trilostane seems comparable to that of healthy dogs.
Collapse
|